Synopsis of recent research by authors named "Silvia Atzeni"
- Silvia Atzeni's recent research focuses on the development of innovative hybrid molecules aimed at addressing the complexities of amyotrophic lateral sclerosis (ALS) through polypharmacology.
- The article published in "ACS Chemical Neuroscience" presents the design and synthesis of multi-target-directed ligands that combine the actions of riluzole and rasagiline, targeting multiple pathological mechanisms in ALS.
- The study highlights the potential of single-molecule solutions in treating ALS by addressing excitotoxicity, mitochondrial dysfunction, oxidative stress, and microglial activation simultaneously.
